Testing effectiveness (Phase 2)Ended earlyNCT02089230
What this trial is testing
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
Who this might be right for
Leukemia
M.D. Anderson Cancer Center 19